On 1 July 2026, Fangda’s client Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, 1877.HK, 688180.SH) announced that it had recently entered into a licensing agreement with Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (“Fosun Wanbang”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, 02196.HK, 600196.SH). Pursuant to the license agreement, the companies will collaborate on the development, registration, manufacturing and commercialization of roconkibart (“JS005”, or “anti-IL-17A monoclonal antibody”) in the Greater China region (including the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region).
Under the terms of the agreement, Junshi Biosciences will grant Fosun Wanbang the rights to develop, register, manufacture and commercialize roconkibart in Greater China. Junshi Biosciences will receive an upfront payment of CNY215 million and will be eligible to receive up to CNY1,125 million in development and sales milestone payments, as well as double-digit tiered royalties based on net sales in the Greater China region.
Roconkibart is a specific anti-IL-17A monoclonal antibody independently developed by the Company. IL (interleukin)-17A is a pleiotropic cytokine, and the disordered secretion of which is closely related to the occurrence and progression of autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis. By binding to IL-17A homodimer and IL-17A/ IL-17F heterodimer with high affinity and selectively blocking the binding of IL-17A with its receptor IL-17RA/IL-17RC, roconkibart blocks the activation of downstream signaling pathways and the release of inflammatory factors, thereby effectively alleviating the symptoms of autoimmune diseases.
The registration for phase III clinical study of roconkibart for treatment on patients with moderate to severe psoriasis in China has completed, showing excellent efficacy and safety level. In 150 mg dosing group, the PASI 90 response rate at week 16 reached 91%; the PASI 100 response rate at week 52 reached 65%. In December 2025, the new drug application (NDA) for roconkibart for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy was accepted by the National Medical Products Administration (NMPA). As of the date of this announcement, the study follow-up for all subjects under the phase II clinical study of roconkibart for the treatment of ankylosing spondylitis (AS) has completed.
About Junshi Biosciences
Established in December 2012, Junshi Biosciences (688180.SH, 1877.HK) is an innovation-driven biopharmaceutical company committed to developing first-in-class and best-in-class drugs through original innovation. With an outstanding capacity for innovative drug discovery, advanced biotechnology research and development, a whole-industry-chain approach with large-scale production technology, and drug combinations with great market potential, the company has successfully developed an internationally competitive portfolio of drug products and established a tiered pipeline covering therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases and infectious diseases. Its areas of innovation span monoclonal antibodies, small molecules, antibody-drug conjugates (ADCs), bispecific/multispecific antibodies, fusion proteins, nucleic acid drugs, vaccines and other frontier modalities.
About Fosun Pharma
Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, the company focuses on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through its business partner Sinopharm Group, Fosun Pharma also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.
Fangda provided Junshi Biosciences with comprehensive legal services in the transaction, including transaction structure design, as well as the drafting, negotiation, revision and finalization of transaction documents. The Fangda team was led by partners Josh SHIN, Henry HE and Bella WANG. Team members included Ethel WANG, Ida LIU and YUAN Yue.
